Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial - Rosenberg, A; Agrawal, N; Pearson, A T (J Clin Oncol, 2021)
et al.